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The development of a non-sputum-based, point-of-care diagnostic test for tuberculosis
(TB) is a priority in the global effort to combat this disease, particularly in resource-
constrained settings. Previous studies have identified host biomarker signatures which
showed potential, but there is a need to validate and refine these for development as a
test. We recruited 1,403 adults presenting with symptoms suggestive of pulmonary TB at
primary healthcare clinics in six countries from West, East and Southern Africa. Of the
study cohort, 326 were diagnosed with TB and 787 with other respiratory diseases, from
whom we randomly selected 1005 participants. Using Luminex® technology, we
measured the levels of 20 host biomarkers in serum samples which we used to
evaluate the diagnostic accuracy of previously identified and novel bio-signatures. Our
previously identified seven-marker bio-signature did not perform well (sensitivity: 89%,
specificity: 60%). We also identified an optimal, two-marker bio-signature with a sensitivity
of 94% and specificity of 69% in patients with no history of previous TB. This signature
performed slightly better than C-reactive protein (CRP) alone. The cut-off value for a
positive diagnosis differed for human immuno-deficiency virus (HIV)-positive and -negative
individuals. Notably, we also found that no signature was able to diagnose TB adequately
in patients with a prior history of the disease. We have identified a two-marker, pan-African
bio-signature which is more robust than CRP alone and meets the World Healthorg February 2021 | Volume 12 | Article 6078271
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Frontiers in Immunology | www.frontiersin.Organization (WHO) target product profile requirements for a triage test in both HIV-
negative and HIV-positive individuals. This signature could be incorporated into a point-of-
care device, greatly reducing the necessity for expensive confirmatory diagnostics and
potentially reducing the number of cases currently lost to follow-up. It might also
potentially be useful with individuals unable to provide sputum or with paucibacillary
disease. We suggest that the performance of TB diagnostic signatures can be improved
by incorporating the HIV-status of the patient. We further suggest that only patients who
have never had TB be subjected to a triage test and that those with a history of previous
TB be evaluated using more direct diagnostic techniques.Keywords: bio-signature, diagnostic, validation, blood, biomarkers, point of care, M. tuberculosis (M. tb)INTRODUCTION
Tuberculosis (TB) remains a major global health burden with the
World Health Organization (WHO) reporting 10.4 million new
TB cases and 1.6 million TB-related deaths worldwide in 2018.
TB is also the leading cause of death for people infected with the
human immunodeficiency viruses (HIV) (1). The lack of rapid,
accurate, point-of-care diagnostic tests poses a serious challenge
to control efforts (2). The Ziehl Nielsen sputum smear test is
often the only affordable diagnostic tool available in resource
constrained environments, even though its limitations, notably
its low sensitivity, are well publicized (3, 4). Mycobacterium
tuberculosis (M.tb) culture, the reference test, is not widely
available in these settings. It also has several drawbacks which
include a long turnaround time, high costs, and significant rate of
contamination (3). The GeneXpert® MTB/RIF sputum test
(Cepheid, USA), one of the major advances in TB diagnosis,
produces results within 2 h and is coupled with the detection of
rifampicin resistance. The GeneXpert® test is widely available in
developed countries but limitations, including relatively high
operating costs and infrastructural requirements hinder its use in
resource-constrained settings (5, 6). It also has significantly
reduced sensitivity in paucibacillary disease although this has
been somewhat remedied by the newer Xpert Ultra® (7). A
common and very important limitation of the above-mentioned
diagnostic tests is that they are all sputum-based which renders
them unsuitable for use in individuals who have difficulty in
providing good quality sputum. This is particularly true of
children, who typically develop paucibacillary disease (8), and
also of individuals with extra-pulmonary TB or who are HIV-
positive. There is, therefore, an urgent need for alternative
diagnostic tests that are suitable for use in all patient types,
especially in resource-poor settings (9).
Transcriptome-based diagnostic markers have attracted a
good deal of interest as an alternative to current tests. They are
particularly attractive as detection technologies are well
established and require minimal adaptation, irrespective of the
target markers. While this approach shows some promise and
has the advantage of being relatively easy to implement, as a
result of small sample numbers or inappropriate controls, most
studies to date have failed to yield a performance which meets the
requirements of the WHO for a viable diagnostic (10).org 2Immunodiagnostics have received considerable attention as
an alternative for the detection of TB disease in recent years (11,
12). They are particularly promising as they could be developed
into point-of-care tests, which would be easily accessible to
resource limited settings. Such tests would also be useful in
cases where a sputum-based diagnosis (GeneXpert®, smear
microscopy or culture) is difficult or not available (13). The
emergence of interferon gamma release assays (IGRAs) was a
prominent advancement in the development of immunodiagnostic
tools for M.tb. Commercially available IGRAs rely on the reaction
of the immune system to antigens encoded within the region of
difference 1 (RD1) of the M.tb genome, namely early secreted
antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10)
(14). These assays are useful in diagnosis of infection with M.tb,
however, they are of limited value in high TB-endemic areas as they
cannot discriminate between active TB and latent M.tb infection.
Attempts have been made to identify antigens that may be useful in
the diagnosis of active TB (15–17). However, the requirement for
overnight culture precludes the use of these assays as point-of-
care tests.
Host immunological markers detected in ex vivo samples
have shown potential for the diagnosis of TB disease (13, 18–21).
These markers may be incorporated into a field-friendly, point-
of-care test based on finger-prick blood and lateral flow
technology. One such test, currently under development, relies
on a seven-marker host bio-signature identified in serum (20).
However, tests based on large signatures such as this are
expensive, complex to design and manufacture and rely on the
continued production of numerous components by suppliers. It
would, therefore, be of benefit to devise a small, reliable bio-
signature implementable in a test device that would be cost-
effective and relatively simple to produce. One such signature
that has been previous identified in a high-TB incidence setting
in HIV-positive participants is C-reactive protein (CRP) (22). It
appears to be one of the more promising markers and
consequently worth validating in this study in a broader context.
An important characteristic of TB, which complicates its
diagnosis, is its frequent association with HIV infection (23).
Any diagnostic test that is to be useful should be capable of
detecting TB in both HIV-positive and -negative patients.
Immunological responses of patients to M.tb may differ,
dependent on their genetic profiles as well as the bacterialFebruary 2021 | Volume 12 | Article 607827
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important that a diagnostic test be sufficiently robust as to
yield valid results irrespective of host-genetic background and
prevalent M.tb strains.
This study investigated the potential of several previously
identified, serum protein host markers to detect pulmonary TB
in patients presenting at primary healthcare clinics, in seven sites
across six African countries, with symptoms indicating possible
TB (20). We further aimed to investigate the diagnostic potential
of modified bio-signatures identified by us and combinations of
other markers from the literature (20, 21). The study comprised a
large cohort of HIV-negative and HIV-positive participants from
different regions of the African continent in order to ensure that
any bio-signature identified would be widely applicable in a
point-of-care test for TB disease.Frontiers in Immunology | www.frontiersin.org 3METHODS
Study Participants
We prospectively recruited 1,403 adults (18 years or older)
(Figure 1), presenting with symptoms suggestive of pulmonary
TB disease at primary healthcare clinics at seven field sites in six
African countries as previously described (20). Both HIV-
positive and -negative participants were included. Participants
in this study were recruited as part of the EDCTP-funded
African-European Tuberculosis Consortium (AE-TBC) which
included Stellenbosch University (SUN), South Africa; Makerere
University, Uganda (UCRC); Medical Research Council Unit,
The Gambia at the London School of Hygiene and Tropical
Medicine (MRCG); Karonga Prevention Study (KPS), Malawi;
University of Namibia (UNAM), Namibia; Ethiopian Health andFIGURE 1 | STARD diagram showing the study design and classification of study participants. TB, pulmonary TB; ORD, individuals presenting with symptoms and
investigated for pulmonary TB but in whom TB disease was ruled out; ROC, receiver operator characteristic. STARD, Standards for Reporting of Diagnostic Accuracy.February 2021 | Volume 12 | Article 607827
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Armauer Hansen Research Institute (AHRI), Ethiopia.
Criteria for inclusion in the study were a cough persisting for
more than 2 weeks together with any one of the following: fever,
recent weight-loss, night-sweats, hemoptysis, chest-pain, or
anorexia. Participants were included in the study if they were 18
years or older, willing to give written informed consent, including
for HIV testing using a rapid test (Abbott, Germany), and sample
storage. Exclusion criteria for the study included severe anemia
(hemoglobin <10g/l), pregnancy, other known chronic diseases such
as diabetes mellitus, current anti-TB treatment, anti-TB treatment
in the last 3 months, use of quinolone or aminoglycoside antibiotics
in the past 2 months, or residency in the study area for less than 3
months. Study participants were recruited between November 2010
and November 2012.
Approval for the study was granted by the Human Research
Ethics Committee of Stellenbosch University (N10/08/274) as well
as the ethics committees of the respective partner institutions.
Classification of Study Participants
Prior to the commencement of recruitment, harmonized case
definitions were established to be used for the classification of
study participants at all study sites. Using a combination of
clinical, radiological, and laboratory findings, participants were
classified as either definite TB cases, probable TB cases, or other
respiratory disease (ORD) as previously described (20). The
ORD cases were participants diagnosed as having a range of
other respiratory conditions including upper and lower
respiratory tract bacterial or viral infections (although no
attempt was made to identify organisms by culture), and acute
exacerbations of chronic obstructive pulmonary disease or
asthma. In assessing the diagnostic accuracy of the markers
investigated in the present study, all the definite and probable
TB cases were classified as “TB,” and then compared to the ORD
cases (Figure 1). Participants who could not be diagnosed with
an acceptable degree of certainty due to insufficient or
contradictory clinical evidence (Table 2) were excluded from
the analysis.
Reading of Chest X-Rays
Each chest X-ray was reviewed by research medical officers at each
site, who decided whether the quality was adequate for classification
and then classified it as either normal, abnormal and suggestive of
active TB, or abnormal and not suggestive of active TB. Repeat
X-rays were compared to baseline X-rays and classified as wither
resolved, improved, unchanged, or deteriorated. Lesion types were
also documented for abnormal X-rays. The central study clinician
reviewed X-rays of all participants whose main study classification
(definite TB, probable Tb, No TB) was dependent on the chest
X-ray findings. Cases in which the central study clinician’s opinion
differed from that of the research medical officer were discussed
with the study PI.
Sample Collection and Microbiological
Diagnostic Tests
Harmonized protocols were used for collection and processing of
samples across all study sites. Briefly, blood samples wereFrontiers in Immunology | www.frontiersin.org 4collected at first contact with the patient in 4ml plain BD
Vacutainer serum tubes (BD Biosciences) and transported
within 3 h at ambient temperature to the laboratory. Tubes
were then centrifuged at 2,500 rpm for 10 min, after which serum
was harvested, aliquoted into bar-coded cryotubes, and frozen at
–80°C until use. Sputum samples were collected from all
participants and cultured using either the Mycobacteria growth
indicator tube (MGIT) method (BD Biosciences) or Lowenstein–
Jensen media, depending on facilities available at the study site.
Specimens demonstrating growth of micro-organisms were
examined for acid-fast bacilli using the Ziehl–Neelsen method
followed by either Capilia TB testing (TAUNS, Numazu, Japan)
or polymerase chain reaction (PCR) to confirm the isolation of
organisms of the M.tb complex before being designated as
positive cultures.
Luminex® Multiplex Immunoassay
Using Luminex® technology, we measured the levels of 20 host
biomarkers using antibodies supplied by Merck Millipore,
Billerica, Massachusetts, USA and R&D Systems, Minneapolis,
Minnesota, USA (Table 1). All samples were evaluated undiluted
or diluted according to the manufacturers recommendations.
Samples were randomized to assay plates with the experimenter
blinded to sample data. All assays were performed and read in a
central laboratory (SUN) on the Bio-Plex platform (Bio-Rad),
with the Bio-Plex Manager Software (ver. 6·1) used for bead
acquisition and analysis.
Data Management and Statistical Analysis
All participant and laboratory data were captured using a central
REDCap database hosted at SUN (25). Participant and sample
management was done using a multi-site study management
REDCap plugin application developed at SUN.TABLE 1 | Host markers evaluated in this study nomenclature.
Abbreviation Full Name
Merck Millipore, Billerica, Massachusetts, USA
CRP C-reactive protein
SAA Serum amyloid A
SAP Serum amyloid P component
FIBR Fibrinogen
NCAM Neural cell adhesion molecule
ApoA1 Apolipoprotein A1
Apo-CIII Apolipoprotein C-III
CFH Complement factor H
R&D Systems, Minneapolis, Minnesota, USA
TGF-a Transforming growth factor alpha
IFN-g Interferon gamma
IP-10 IFN-g-inducible protein
TNF-a Tumour necrosis factor alpha
Serpin C Serpin C
Ferritin Ferritin
CCL14/HCC-1 Chemokine (C-C motif) ligand 14
CCL1/I-309 Chemokine (C-C motif) ligand 1
MIG/CXCL9 Monokine induced by gamma interferon
VEGF-A Vascular endothelial growth factor A
BNDF Brain-derived neurotrophic factor
GDF15 Growth/differentiation factor 15February 2021 | Volume 12 | Article 607827
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Team (2019). R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Austria. URL https://www.R-project.org/] working in the
RStudio (ver. 1·2·5019) environment (RStudio Team (2019),
RStudio: Integrated Development for R. RStudio, Inc., Boston,
MA URL http://www.rstudio.com/) running on Kubuntu Linux
19·04. Unless otherwise stated, graphs were produced using the
ggplot2 package (ver. 3·2·1). Parallel processing was facilitated by
the doParallel package.
Missing values for SAA fluorescence data were imputed for 42
records using the missForest package using sex, age, HIV status,
TB status, and all analytes as predictors.
Due to the presence of a few extreme fluorescence values for
some of the analytes, the fluorescence data were subjected to
winsorization whereby values greater than 10 median absolute
deviations from the median were proportionally shrunk toward
the median absolute deviation as calculated with the exclusion of
the outliers.
Data were randomly divided into a training set (60%) and a
test set (40%). Representivity of each study site in the training set
ranged from 55 to 66% of the site’s data.
Sparse Linear Discriminant Analysis (sparseLDA) models
were trained using the Caret package (ver. 6.0-84) with
predictor variables normalized using the YeoJohnson
transformation, centered and scaled. Smote resampling was
used to balance the proportions of TB and non-TB cases.
Models were optimized for maximum sensitivity at a
minimum specificity of 0.7 using a customized version of
Caret’s twoClassSummary function.
A model based on a previously published combination of 7
markers was trained using 32-times repeated, 10-fold cross-
validation to select the optimal number of terms and the value
for the regularization parameter, lambda. The model allowed
interactions between the predictors.
An optimal model was developed by first selecting a set of
markers by training a model using 32-times repeated, 10-fold
cross-validation without interactions. These markers were then
used to generate a new model, which allowed interactions
between the predictors, using cross-validation to select the
optimal number of terms and value for the regularization term,
lambda, which reduces the risk of overfitting.
A model, weighted to compensate for the lower prevalence of
HIV-positive cases in the dataset, was generated similarly, butFrontiers in Immunology | www.frontiersin.org 5with the addition of a weights vector to the caret::train function.
HIV-positive cases were assigned a weight inversely proportional
to the number of HIV-positive cases and likewise for HIV-
negative cases.
Receiver-operator characteristic (ROC) curves were produced
using the pROC package. The 95% confidence intervals for
sensitivity were generated by bootstrap resampling (R=10,000).
Optimal cut-off values were selected as the highest sensitivity
such that specificity remained above 70% where possible. Area
under the curve (AUC) values were compared using the
bootstrap method.RESULTS
Clinical and Demographic Characteristics
of Study Participants
In the current study we recruited a total of 1,403 participants
(Figure 1). Of these, 196 participants were excluded due to the
unavailability of data or samples. Using pre-established case
definitions (Table 2), 268 (22.2%) of the remaining 1,207 study
participants were classified as definite pulmonary TB cases and
58 (4.8%) as probable TB cases, together representing the active
TB group (326 participants; 27.0%). 787 (65.2%) were classified
as ORD cases. Ninety-four (7·8%) participants could not be
reliably classified due to incomplete data or loss to follow-up and
were excluded from the study. 1,005 of the remaining
participants were randomly selected for further analysis.
Demographic and clinical details of the participants are given
in Table 3.
Performance of Individual Serum
Biomarkers in the Diagnosis of TB Disease
Using the training data-set, 17 of the 20 serum markers
investigated in the study showed significant differences
(p<0.0025 corrected for multiple testing) between the TB and
ORD cases, irrespective of HIV infection status or country of
sample origin. Those that did not were IFN-g, ApoA-1, and
Serpin C1. When we investigated the ability of the markers to
diagnose TB disease using ROC curve analysis, the areas under
the ROC curve (AUC) were between 0.70 to 0.86 for 12 out of the
20 investigated analytes, namely; ApoCIII, BNDF, I-309, CRP,
IP-10, MIG, ferritin, fibrinogen, IFN-g, SAA, SAP, and TNF-a
(Figures 2 and 3).
Performance of Serum Multi-Analyte
Models in the Diagnosis of TB Disease
Performance of the Optimal Bio-Signature
In order to identify the best performing marker combination, we
generated a model using the sparseLDA algorithm with no
constraint on marker number. This identified a two-marker,
optimal bio-signature. The selected markers were: I-309 and
CRP. We constructed a sparseLDA model from these markers,
including interactions between terms, which yielded a sensitivity
of 93% and a specificity of 68% on the test set. The area under the
ROC curve (AUC) for this model was 0·90 (Table 4) (26).TABLE 2 | Classification definitions used to identify study participants groups.
Classification Definition
Definite TB Sputum culture-positive for MTB.
OR2 positive smears and symptoms responding to TB
treatment.
OR1 positive smear plus CXR suggestive of PTB
Probable TB 1 positive smear and symptoms responding to TB treatment.
ORCXR evidence and symptoms responding to TB treatment.
ORD Negative cultures, negative smears, negative CXR and
treatmentnever initiated by healthcare providersCXR, chest X-ray; MTB, Mycobacterium tuberculosis; ORD, other respiratory disease; TB,
pulmonary TB. (Reproduced from Chegou et al., Thorax 2016) (20).February 2021 | Volume 12 | Article 607827
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for HIV-positive participants was different to that for HIV-
negatives. In order to maximize the performance of the model,
it was therefore necessary to choose separate cut-off values for
these two groups. The model then yielded sensitivities and
specificities of 91 and 73% for HIV-negative cases and 87 and
64% for HIV-positive cases respectively (Table 4; Figure 4).
Attempting to improve the model’s performance on HIV-
positive cases by weighting their contribution to the model by
the inverse of their proportion during training did not produce
any noticeable effect.
Performance of the Best Bio-Signature Without CRP
To determine the degree of dependence on CRP, we repeated the
optimal model construction, excluding CRP from the available
set of markers. In this scenario, the algorithm selected I-309,
NCAM and SAA. The performance of this signature was
marginally inferior to, that of the optimal signature in both
HIV-negative and HIV-positive individuals (Table 4, Figure S3).
Weighting the data to increase the contribution of HIV-positive
cases did not significantly improve the performance of the model
on this group.
Performance of the Previously Identified Seven-
Marker Bio-Signature
We previously identified a seven-marker bio-signature
comprising: ApoA-1, CFH, CRP, IFN-g, IP-10, SAA, and
transthyretin (20). This had a sensitivity and specificity of 93.8
and 73.3% respectively when the model was applied to a test set.
The data for that study was generated from an early-recruitment
subset of the samples used in the current study, from five of the
seven field-sites. We investigated the diagnostic potential of the
seven-marker serum bio-signature, with transthyretin removed,
as antibodies for this marker were no longer available for
Luminex®. To do this, we used a 60% training set which was a
super-set of samples from the participants common to this and
the original study. Model performance was evaluated on a test set
comprising the remainder of the samples in the current study.
These had not been part of the original study. This signature did
not perform well. The sensitivity and specificity in HIV-negative
individuals was 88 and 61% respectively and in HIV-positive
individuals, 80 and 57% (Table 4; Figure 5).Frontiers in Immunology | www.frontiersin.org 6Performance of CRP
We built a model to validate the previously identified single
diagnostic marker, CRP (22). We found a sensitivity of 89% and
specificity of 75% in HIV-negative participants and 90 and 67%
respectively when tested against HIV-positive participants
(Table 4; Figure 6).
Performance with Respect to History of Previous TB
We investigated the performance of the optimal model separately
on participants with a history of previous TB and those without.
We found that the bio-signature performed well for participants
with no history of previous TB. For HIV-positive participants,
we achieved a sensitivity of 95% and a specificity of 64% and for
HIV-negatives, a sensitivity of 93% and specificity of 76% (Table
4; Figure 7). For participants with a previous episode of TB,
however, the bio-signature was far less informative. In this case,
for HIV-positive participants, we measured a sensitivity of 70%
and a specificity of 73%, while for HIV-negatives, the values were
82 and 68% respectively (Table 4; Figure 8). The optimal bio-
signature therefore met the requirements of the WHO TPP for a
triage test in patients without a history of previous TB, although
the specificity for HIV-positive patients was slightly lower than
desired (26).
Comparison of Model Performance
In comparing the AUCs of the ROC curves of the various
models, we found that the optimal signature significantly out-
performed CRP on its own (p=0.032, stratified bootstrap). This
was also the case when we compared the sensitivities of these two
models at a specificity of 0.7 (p=0.032, stratified bootstrap).
There were no significant pairwise differences between any of
the other models.DISCUSSION
The development of a better diagnostic tool for TB is an
important goal in the fight against this disease. To this end, we
investigated the ability of 20 previously identified host serum
protein biomarkers to diagnose TB disease in individuals
presenting with symptoms suggestive of TB disease at
peripheral healthcare clinics in six African countries. Twelve ofTABLE 3 | Clinical and demographic characteristics of analyzed study participants from the seven study sites.
Study site AHRI EHNRI KPS MRCG SUN UCRC UNAM Total
Participants 149 185 109 188 156 170 46 1003
Age in years, mean ± SD 33·4 ± 11·6 35·1 ± 14·7 39·7 ± 13·8 35·4 ± 12·6 37·5 ± 11·5 32·6 ± 9·9 35·6 ± 11·0 35·4 ± 12·5
Males, n (%) 75 (50·3) 76 (41·1) 56 (51·3) 109 (58·0) 64 (41·0) 87 (51·2) 27 (58·7) 494 (49·3)
Previous TB, n (%) 20 (13·4) 19 (10·2) 9 (8·3) 14 (7·4) 65 (41·7) 4 (2·4) 11 (23·9) 142 (14·2)
HIV pos TB pos, n (%) 6 (10·7) 13 (24·1) 12 (60·0) 8 (15·1) 4 (16·0) 7 (11·3) 15 (58·3) 71 (25·5)
HIV pos TB neg, n (%) 5 (4·1) 16 (12·0) 49 (55·7) 9 (6·7) 24 (18·3) 21 (19·4) 5 (50·0) 129 (17·8)
Definite TB, n (%) 28 (18·8) 53 (28·6) 17 (15·6) 44 (23·4) 21 (13·5) 58 (34·1) 31 (67·4) 252 (25·1)
Probable TB, n (%) 0 (0) 0 (0) 3 (2·8) 9 (4·8) 4 (2·6) 4 (2·4) 5 (10·9) 25 (2·5)
Total TB, n (%) 28 (18·8) 53 (28·6) 20 (18·3) 53 (28·2) 25 (16·0) 62 (36·5) 36 (78·3) 277 (27·6)
ORD, n (%) 121 (81·2) 132 (71·4) 89 (81·7) 135 (71·8) 131 (84·0) 108 (63·5) 10 (21·7) 726 (72·4)
ORD QFTpos/tested, (%) ND ND 29/86 (33·7) 40/129 (31·0) 86/127 (67·7) 59/104 (56·7) 7/10 (70·0) 224/456 (49·1)February 2021 | Volume 12 |TotalTB, sum of definite and probable TB cases; ORD QFT, quantiferon results for ORD participants.Article 607827


































FIGURE 2 | Receiver-operator characteristic (ROC) curves of the diagnostic performance of the individual biomarkers in the train
cut-off point.
Mutavhatsindi et al. Immunological Diagnostic Bio-Signature for TBthe 20 investigated biomarkers showed promise in this study for
diagnosing TB disease as their ROC curves when distinguishing
between the TB and ORD groups had AUCs greater than 0.7.
Although many biomarkers obtained from various body-fluids
show promise individually for diagnosing TB, single markers tendFrontiers in Immunology | www.frontiersin.org 8to be less robust than combination bio-signatures due to their non-
specificity and tendency to be affected by other factors such as HIV-
infection (20). This was the case when we attempted to validate the
previously identified biomarker, CRP, which was less effective at
diagnosing TB than the optimal two-marker model.FIGURE 3 | Fluorescent intensities on a log scale of biomarkers detected in the serum samples of participants with tuberculosis (TB) and those with other
respiratory disease (ORD), for all 20 markers analyzed. Unadjusted permutation test p-values for the difference between the means of the groups are given for each
biomarker (105 permutations).TABLE 4 | Performance of the predictive models.
Signature N AUC (95% CI) Sensitivity (95% CI) Specificity (95% CI)
CRP 401 0·85 (0·81-0·88) 0·85 (0·81-0·88) 0·74 (0·54-0·84)
HIV pos 85 0·79 (0·70-0·87) 0·83 (0·56-0·93) 0·72 (0·39-0·83)
HIV neg 316 0·86 (0·81-0·90) 0·86 (0·79-0·92) 0·70 (0·54-0·85)
6-marker 350 0·85 (0·80-0·90) 0·89 (0·81-0·96) 0·60 (0·34-0·82)
HIV pos 41 0·80 (0·65-0·92) 0·80 (0·65-0·95) 0·57 (0·14-0·95)
HIV neg 309 0·85 (0·79-0·91) 0·88 (0·80-0·96) 0·61 (0·29-0·85)
Optimal 401 0·90 (0·86-0·94) 0·93 (0·87-0·97) 0·68 (0·36-0·82)
HIV pos 85 0·89 (0·80-0·95) 0·87 (0·73-1·00) 0·64 (0·47-0·89)
HIV neg 316 0·90 (0·86-0·94) 0·91 (0·84-0·98) 0·73 (0·40-0·89)
No Previous TB 338 0·92 (0·88-0·95) 0·94 (0·89-0·99) 0·69 (0·36-0·87)
HIV pos 64 0·92 (0·84-0·97) 0·95 (0·85-1·00) 0·64 (0·50-0·89)
HIV neg 274 0·92 (0·87-0·96) 0·93 (0·86-0·99) 0·74 (0·43-0·92)
Previous TB 63 0·83 (0·70-0·93) 0·81 (0·67-1·00) 0·60 (0·29-0·93)
HIV pos 21 0·84 (0·62-0·97) 0·70 (0·40-1·00) 0·73 (0·27-1·00)
HIV neg 42 0·79 (0·60-0·95) 0·82 (0·45-1·00) 0·68 (0·13-0·97)
Optimal Excluding CRP 401 0·89 (0·85-0·94) 0·92 (0·86-0·97) 0·70 (0·47-0·84)
HIV pos 85 0·88 (0·79-0·94) 0·93 (0·77-1·00) 0·56 (0·40-0·84)
HIV neg 316 0·89 (0·84-0·93) 0·89 (0·81-0·96) 0·77 (0·52-0·92)February 2021 | VolumSignatures: Six-marker (ApoA-1, CFH, CRP, IFN-g, IP-10, SAA), optimal (I-306 and CRP), optimal excluding CRP (I-309, NCAM and SAA). N=test-set samples.e 12 | Article 607827
Mutavhatsindi et al. Immunological Diagnostic Bio-Signature for TBWe identified an optimal diagnostic bio-signature,
irrespective of African country of origin, comprising two
markers: the chemoattractant, I.309 and CRP. This signature
meets the WHO minimum requirements for a triage test, which
is a sensitivity of 90% and specificity of 70%, in HIV-negative
patients and in HIV-positive patients with no previous history of
TB (26). Given the frequent co-morbidity of TB and HIV
infection and the difficulties this creates for diagnosing TB, it
is encouraging that our diagnostic bio-signature is successful
regardless of HIV infection status, albeit with wider confidence
intervals in the case of HIV positive participants. It should be
noted, however, that I.309 is present in blood at far lowerFrontiers in Immunology | www.frontiersin.org 9concentrations than CRP which poses a technological
challenge for measurement in a point-of-care device.
The poor performance that we observed for our bio-signature
in participants with a history of previous TB has not, as far as we
are aware, been previously reported and raises the question as to
whether any surrogate biomarker for TB disease can perform
well in patients in this category. It is worth noting that this is a
limitation shared by the Xpert Ultra® technology (27). The
number of patients falling into this group in the test set was
small (n=63) which may explain the lack of significant difference
in the performance of the model between this and the first-time
TB group. However, it is also possible that this group had anFIGURE 4 | Receiver-operator characteristic (ROC) curve for the optimal bio-signature (CRP and I-309) for HIV-positive (N=85) and HIV-negative (N=316) individuals.
The optimal sensitivity and specificity are shown on the bottom right corner together with the negative and positive predictive values.FIGURE 5 | Receiver-operator characteristic (ROC) curve for the modified seven marker bio-signature originating from Chegou and colleagues, excluding
transthyretin, for HIV-positive (n=41) and HIV-negative (n=309) individuals (20). The optimal sensitivity and specificity bottom right together with the negative and
positive predictive values.February 2021 | Volume 12 | Article 607827
Mutavhatsindi et al. Immunological Diagnostic Bio-Signature for TBinherently greater variability in marker levels leading to the very
wide observed confidence intervals. Considering that most
candidate markers for active TB are related to inflammation
and that previous TB episodes often cause chronic lung damage,
in turn leading to chronic inflammation, it is not entirely
unexpected that the performance of these markers could be
influenced by previous TB episodes. These preliminary
findings will need to be confirmed by further studies. Since it
has been established that a prior episode of TB tends to increase
the risk of a repeat episode, it could be argued that such patients,
on presenting with suspected TB, should bypass the triage test
and be referred for confirmatory testing (28). It would be
interesting to know whether the time elapsed since the
previous episode affects the predictive power of the test.Frontiers in Immunology | www.frontiersin.org 10However, this will need to be examined in a follow-up
investigation as this data was not available in the present study.
Yoon et al. previously reported on a CRP-based point-of-care
screening test for TB (89% sensitivity and 72% specificity with a
pre-determined threshold of 10mg/L) in antiretroviral therapy-
naive, HIV-infected individuals with low CD4-cell counts from
Uganda (22). We found CRP to be a common factor in, and
indeed, the most important component of all our bio-signatures.
When we excluded this marker from use by the modeling
algorithm, we observed a slight, but non-significant, decrease
in discriminatory power of the resultant model as has been
previously reported (29). While raised levels of CRP are by no
means specific to TB, this marker does appear to be the strongest
differentiator between this and other lung diseases. An advantageFIGURE 6 | Receiver-operator characteristic (ROC) curve for CRP only for HIV-positive (N=85) and HIV-negative (N=316) individuals. The optimal sensitivity and
specificity are shown on the bottom right corner together with the negative and positive predictive values.FIGURE 7 | Receiver-operator characteristic (ROC) curves of the performance of the optimal bio-signature (CRP and I-309) for HIV-positive (n=64) and HIV-negative
(n=274) individuals with no previous history of TB. The optimal sensitivity and specificity are shown on the bottom right corner of each ROC curve together with the
negative and positive predictive values.February 2021 | Volume 12 | Article 607827
Mutavhatsindi et al. Immunological Diagnostic Bio-Signature for TBof CRP as a biomarker is its applicability, regardless of HIV
infection status, due to its lack of dependence on the presence of
CD4 cells (29). This feature, however, is not unique to CRP as
other biomarkers such as IP-10, SAA, and ferritin are also
produced in the context of HIV infection and may, therefore,
be suitable substitutes (30, 31). It seems clear, however, that any
serum protein-based bio-signature is likely to require the
inclusion of CRP, but that additional markers may aid in
boosting its performance above the WHO’s TPP threshold.
Ideally, a point-of-care test would be capable of analyzing a
raw, unprocessed sample such as finger-prick blood. Given that
the current results are based on serum analyzed using a highly
sophisticated laboratory instrument, it is likely that any point-of-
care test based on the same analytes would demonstrate different
characteristics, resulting in a possible loss of performance in
translation to the final product. However, the significant degree
of correlation between many immunological biomarkers means
that it would be quite possible to substitute a marker which did
not perform as desired in the end-product device with an
alternative. It should also be noted that the performance of our
bio-signatures exceeded the minimum criteria by a considerable
degree in three of the sites which suggests that there may be some
margin for loss of performance without dropping below
these values.
Our attempt to validate our previously reported, seven-marker
bio-signature was not successful. This failure may partially be
explained by the necessary exclusion of transthyretin, which was
an important component of the original signature, but was not
available on the Luminex® platform. Nevertheless, this result
highlights the importance of subjecting promising results to
validation on independent datasets.
A major strength of this study is the diversity of the study
sites, including participants from East, West, and Southern
Africa. We were able to demonstrate that our bio-signaturesFrontiers in Immunology | www.frontiersin.org 11performed well in sites from all three African regions, although
performance in three sites (KPS, UNAM, and EHNRI) was less
than optimal. This is particularly pertinent as Africa accounts for
16 of the 30 countries with a high burden of TB and is also
subject to resource limitations, making a point-of-care test highly
beneficial in this context (1). Site-specific performance of the
optimal model is presented in the supplemental data (Figure S2).
The under-performance of the bio-signatures in certain sites is
a source of some concern. In the case of UNAM, participant
numbers were approximately half that of the other sites with the
result that there were only 19 participants from this site in the test
set. In addition, due to overly rigorous screening at this site, only
22% of participants fell into the ORD group. In addition, UNAM
and KPS had much higher proportions of HIV-positive
participants than the other sites which may have negatively
impacted their results. It should also be noted that these three
sites experienced a number of logistical difficulties such as remote
location, unreliable power supply, and less experienced staff which
may have impacted on the quality of the samples and data.
The pan-African performance of our bio-signature is very
encouraging, however, it remains to be seen whether this success
translates to other settings where differing conditions or
population genetics may have a negative impact. It also remains
for the bio-signature identified in this study to be validated using
finger-prick blood and technology appropriate to a point-of-care
test. Further studies addressing these questions are in progress.
Being blood-based, rather than requiring the production of
sputum, our bio-signature may also prove to be useful in
children, who typically develop paucibacillary disease, as well as
in individuals presenting with extra-pulmonary TB. Performance
in these cohorts should be addressed once the signature has been
validated in field-tests in adult pulmonary TB patients.
A potential source of error in this study, and others of this
nature, stems from the existence of a subgroup of participantsFIGURE 8 | Receiver-operator characteristic (ROC) curves of the performance of the optimal bio-signature (CRP and I-309) for HIV-positive (n=21) and HIV-negative
(n=42) individuals with a history of previous TB. The optimal sensitivity and specificity are shown on the bottom right corner of each ROC curve together with the
negative and positive predictive values.February 2021 | Volume 12 | Article 607827
Mutavhatsindi et al. Immunological Diagnostic Bio-Signature for TBwhose diagnosis is uncertain. A rule-out test, such as the one
proposed here, ought to classify these as TB so that they would be
subject to further investigation. Unfortunately, this cannot be
verified as these participants were excluded from this study. This
is a point which should be addressed in a field-trial of the
diagnostic test.
We suggest that the results presented here constitute strong
evidence that the development of a TB triage diagnostic test
based on a small number of immunological biomarkers is
feasible. Such a tool would be of substantial benefit,
particularly in under-resourced setting, which tend to have the
highest burden of disease, by reducing the number of
unnecessary referrals for expensive, confirmatory diagnostics
such as GeneXpert®. As a result of its rapid turn-around time,
it would also have the benefit of reducing the number of TB cases
currently lost to follow-up which, in turn, would decrease the
infection pressure in the affected communities.SCREENTB CONSORTIUM
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